Quote:

---

Let's say the DSMB recommends that everyone gets put on 700 mg, which I trust will happen. That info would of course be available to the CRO, who would have to carry it out. Would CYDY know that 700 mg has signalled "superior activity"? Would it be bad faith or even degrade the trial if the company announced that fact about a month + into the trial?

---

Since the dosage would be equivalent for all patients it would not affect trial outcome if only that were known. There would be no reason to not let Cytodyn or the general population know.